GlassScriptPhysician profile
Ronald Paul Cramer
NPI 1275586000
$2,443.87
in general payments reported to CMS, 2019-2025
28 companies · $755 in 2025
The $755 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173 · 2020: $286 · 2021: $284 · 2022: $251 · 2023: $206 · 2024: $488 · 2025: $755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,449.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $882.69 | 2020-2025 | Rinvoq, Mavyret, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $315.68 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $172.11 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $163.04 | 2021-2025 | Entyvio, Eohilia |
| Boston Scientific Corporation | $134.30 | 2019-2021 | |
| Ardelyx, INC. | $131.61 | 2024-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $98.64 | 2020-2024 | Rebyota |
| Intercept Pharmaceuticals, INC. | $47.24 | 2019-2025 | |
| Gilead Sciences, INC. | $44.96 | 2019-2021 | |
| Genzyme Corporation | $43.66 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $42.02 | 2023-2024 | Dificid |
| Cumberland Pharmaceuticals, INC. | $38.92 | 2019-2020 | |
| Celltrion USA INC. | $38.08 | 2025 | Vegzelma |
| Regeneron Healthcare Solutions, INC. | $32.39 | 2022 | |
| Ironwood Pharmaceuticals, INC | $31.28 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $29.08 | 2021 | |
| Redhill Biopharma INC. | $27.33 | 2020-2021 | |
| Madrigal Pharmaceuticals | $22.17 | 2025 | Rezdiffra |
| Lilly USA, LLC | $20.79 | 2025 | Omvoh |
| Daiichi Sankyo INC. | $20.05 | 2019 | |
| Vivus LLC | $18.62 | 2024 | Qsymia |
| Celgene Corporation | $15.95 | 2022 | |
| Pfizer INC. | $12.70 | 2020 | |
| Paratek Pharmaceuticals, INC. | $12.67 | 2020 | |
| Axonics, INC. | $12.65 | 2021 | |
| Acelrx Pharmaceuticals, INC. | $12.01 | 2019 | |
| Echosens North America, INC. | $11.85 | 2023 | Fibroscan |
| Phathom Pharmaceuticals, INC. | $11.38 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Cramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.